Cargando…

Cyclic changes in gene expression induced by Peg-interferon alfa-2b plus ribavirin in peripheral blood monocytes (PBMC) of hepatitis C patients during the first 10 weeks of treatment

BACKGROUND AND AIMS: This study determined the kinetics of gene expression during the first 10 weeks of therapy with Pegylated-interferon-alfa2b (PegIntron™) and ribavirin (administered by weight) in HCV patients and compared it with the recently completed Virahep C study [1,2] in which Peginterfero...

Descripción completa

Detalles Bibliográficos
Autores principales: Taylor, Milton W, Tsukahara, Takuma, McClintick, Jeanette N, Edenberg, Howard J, Kwo, Paul
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2613871/
https://www.ncbi.nlm.nih.gov/pubmed/18986530
http://dx.doi.org/10.1186/1479-5876-6-66
_version_ 1782163201204420608
author Taylor, Milton W
Tsukahara, Takuma
McClintick, Jeanette N
Edenberg, Howard J
Kwo, Paul
author_facet Taylor, Milton W
Tsukahara, Takuma
McClintick, Jeanette N
Edenberg, Howard J
Kwo, Paul
author_sort Taylor, Milton W
collection PubMed
description BACKGROUND AND AIMS: This study determined the kinetics of gene expression during the first 10 weeks of therapy with Pegylated-interferon-alfa2b (PegIntron™) and ribavirin (administered by weight) in HCV patients and compared it with the recently completed Virahep C study [1,2] in which Peginterferon-alfa2a (Pegasys™) and ribavirin were administered. METHODS: RNA was isolated from peripheral blood monocytes (PBMC) from twenty treatment-naïve patients just before treatment (day 1) and at days 3, 6, 10, 13, 27, 42 and 70 days after treatment. Gene expression at each time was measured using Affymetrix microarrays and compared to that of day 1. RESULTS: The expression of many genes differed significantly (p ≤ 0.001 and changed at least 1.5-fold) at days 3 (290 probes) and 10 (255 probes), but the number dropped at days 6 (165) and 13 (142). Most genes continued to be up regulated throughout the trial period. A second group of genes, including CXCL10, CMKLR1 (chemokine receptor 1), TRAIL, IL1Rα and genes associated with complement and lipid metabolism, was transiently induced early in treatment. CDKN1C (cyclin kinase inhibitor 1) was induced early but repressed at later times. Genes induced at later times were mostly related to blood chemistry and oxygen transport. By week 10, 11 of the patients demonstrated a positive response to therapy, and the final sustained viral response (SVR) was 35%. The levels of gene induction or decrease was very similar to that previously reported with Pegasys/ribavirin treatment. CONCLUSION: The response to Pegintron/ribavirin was similar to that reported for Pegasys/ribavirin despite some differences in the amount administered. We did not detect major differences at the genomic level between patients responding to treatment or non-responders, perhaps because of limited power. Gene induction occurred in a cyclic fashion, peaking right after administration of interferon and declining between administrations of the drug. Our data suggest that more than once a week dosing might be desirable early during treatment to maintain high levels of response as measured by gene expression.
format Text
id pubmed-2613871
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-26138712009-01-06 Cyclic changes in gene expression induced by Peg-interferon alfa-2b plus ribavirin in peripheral blood monocytes (PBMC) of hepatitis C patients during the first 10 weeks of treatment Taylor, Milton W Tsukahara, Takuma McClintick, Jeanette N Edenberg, Howard J Kwo, Paul J Transl Med Research BACKGROUND AND AIMS: This study determined the kinetics of gene expression during the first 10 weeks of therapy with Pegylated-interferon-alfa2b (PegIntron™) and ribavirin (administered by weight) in HCV patients and compared it with the recently completed Virahep C study [1,2] in which Peginterferon-alfa2a (Pegasys™) and ribavirin were administered. METHODS: RNA was isolated from peripheral blood monocytes (PBMC) from twenty treatment-naïve patients just before treatment (day 1) and at days 3, 6, 10, 13, 27, 42 and 70 days after treatment. Gene expression at each time was measured using Affymetrix microarrays and compared to that of day 1. RESULTS: The expression of many genes differed significantly (p ≤ 0.001 and changed at least 1.5-fold) at days 3 (290 probes) and 10 (255 probes), but the number dropped at days 6 (165) and 13 (142). Most genes continued to be up regulated throughout the trial period. A second group of genes, including CXCL10, CMKLR1 (chemokine receptor 1), TRAIL, IL1Rα and genes associated with complement and lipid metabolism, was transiently induced early in treatment. CDKN1C (cyclin kinase inhibitor 1) was induced early but repressed at later times. Genes induced at later times were mostly related to blood chemistry and oxygen transport. By week 10, 11 of the patients demonstrated a positive response to therapy, and the final sustained viral response (SVR) was 35%. The levels of gene induction or decrease was very similar to that previously reported with Pegasys/ribavirin treatment. CONCLUSION: The response to Pegintron/ribavirin was similar to that reported for Pegasys/ribavirin despite some differences in the amount administered. We did not detect major differences at the genomic level between patients responding to treatment or non-responders, perhaps because of limited power. Gene induction occurred in a cyclic fashion, peaking right after administration of interferon and declining between administrations of the drug. Our data suggest that more than once a week dosing might be desirable early during treatment to maintain high levels of response as measured by gene expression. BioMed Central 2008-11-05 /pmc/articles/PMC2613871/ /pubmed/18986530 http://dx.doi.org/10.1186/1479-5876-6-66 Text en Copyright © 2008 Taylor et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Taylor, Milton W
Tsukahara, Takuma
McClintick, Jeanette N
Edenberg, Howard J
Kwo, Paul
Cyclic changes in gene expression induced by Peg-interferon alfa-2b plus ribavirin in peripheral blood monocytes (PBMC) of hepatitis C patients during the first 10 weeks of treatment
title Cyclic changes in gene expression induced by Peg-interferon alfa-2b plus ribavirin in peripheral blood monocytes (PBMC) of hepatitis C patients during the first 10 weeks of treatment
title_full Cyclic changes in gene expression induced by Peg-interferon alfa-2b plus ribavirin in peripheral blood monocytes (PBMC) of hepatitis C patients during the first 10 weeks of treatment
title_fullStr Cyclic changes in gene expression induced by Peg-interferon alfa-2b plus ribavirin in peripheral blood monocytes (PBMC) of hepatitis C patients during the first 10 weeks of treatment
title_full_unstemmed Cyclic changes in gene expression induced by Peg-interferon alfa-2b plus ribavirin in peripheral blood monocytes (PBMC) of hepatitis C patients during the first 10 weeks of treatment
title_short Cyclic changes in gene expression induced by Peg-interferon alfa-2b plus ribavirin in peripheral blood monocytes (PBMC) of hepatitis C patients during the first 10 weeks of treatment
title_sort cyclic changes in gene expression induced by peg-interferon alfa-2b plus ribavirin in peripheral blood monocytes (pbmc) of hepatitis c patients during the first 10 weeks of treatment
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2613871/
https://www.ncbi.nlm.nih.gov/pubmed/18986530
http://dx.doi.org/10.1186/1479-5876-6-66
work_keys_str_mv AT taylormiltonw cyclicchangesingeneexpressioninducedbypeginterferonalfa2bplusribavirininperipheralbloodmonocytespbmcofhepatitiscpatientsduringthefirst10weeksoftreatment
AT tsukaharatakuma cyclicchangesingeneexpressioninducedbypeginterferonalfa2bplusribavirininperipheralbloodmonocytespbmcofhepatitiscpatientsduringthefirst10weeksoftreatment
AT mcclintickjeanetten cyclicchangesingeneexpressioninducedbypeginterferonalfa2bplusribavirininperipheralbloodmonocytespbmcofhepatitiscpatientsduringthefirst10weeksoftreatment
AT edenberghowardj cyclicchangesingeneexpressioninducedbypeginterferonalfa2bplusribavirininperipheralbloodmonocytespbmcofhepatitiscpatientsduringthefirst10weeksoftreatment
AT kwopaul cyclicchangesingeneexpressioninducedbypeginterferonalfa2bplusribavirininperipheralbloodmonocytespbmcofhepatitiscpatientsduringthefirst10weeksoftreatment